aTyr Pharma, Inc. (ATYR)
Automate Your Wheel Strategy on ATYR
With Tiblio's Option Bot, you can configure your own wheel strategy including ATYR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATYR
- Rev/Share 0.0
- Book/Share 0.8284
- PB 0.8686
- Debt/Equity 0.1694
- CurrentRatio 5.6334
- ROIC -0.8021
- MktCap 70687558.0
- FreeCF/Share -0.6175
- PFCF -1.2701
- PE -0.9756
- Debt/Assets 0.1249
- DivYield 0
- ROE -0.9345
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ATYR | RBC Capital Mkts | Outperform | Sector Perform | -- | $1.5 | Sept. 16, 2025 |
| Downgrade | ATYR | Leerink Partners | Outperform | Market Perform | -- | $1 | Sept. 15, 2025 |
| Downgrade | ATYR | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Sept. 15, 2025 |
| Downgrade | ATYR | H.C. Wainwright | Buy | Neutral | -- | -- | Sept. 15, 2025 |
| Downgrade | ATYR | Wells Fargo | Overweight | Equal Weight | -- | $1 | Sept. 15, 2025 |
| Initiation | ATYR | Leerink Partners | -- | Outperform | -- | $16 | Feb. 18, 2025 |
| Initiation | ATYR | Cantor Fitzgerald | -- | Overweight | -- | -- | Jan. 6, 2025 |
| Initiation | ATYR | Wells Fargo | -- | Overweight | -- | $17 | Oct. 4, 2024 |
| Initiation | ATYR | Jefferies | -- | Buy | -- | $9 | Sept. 5, 2024 |
News
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease (“ILD”), did not meet its main goal.
Read More
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society Congress 2025
Read More
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman
Published: September 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease (“ILD”), did not meet its main goal.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR).
Read More
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Sept. 23, 2025 /PRNewswire/ -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease ("ILD"), did not meet its main goal.
Read More
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman
Published: September 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease (“ILD”), did not meet its main goal.
Read More
Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma's Phase 3 Clinical Trial Results
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
CHICAGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) expresses both solidarity and resolve as aTyr Pharma announced that its Phase 3 trial of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint but showed several encouraging results that suggest real potential for patients living with this rare disease.
Read More
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FITÔ Study Failure Drives Shares 80% Lower -- Hagens Berman
Published: September 17, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Sept. 17, 2025 /PRNewswire/ -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease ("ILD"), did not meet its main goal.
Read More
INVESTOR ALERT: Investigation of aTyr Pharma, Inc. (ATYR) Announced by Holzer & Holzer, LLC
Published: September 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) complied with federal securities laws. On September 15, 2025, aTyr announced topline results from its Phase 3 EFZO-FIT study, which “did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (“OCS”) dose at week 48.” Following this news, the price of the Company's stock declined.
Read More
ATyr Pharma, Inc. (ATYR) Announces Top Line Results For The Phase III EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis (Transcript)
Published: September 15, 2025 by: Seeking Alpha
Sentiment: Neutral
aTyr Pharma, Inc. (NASDAQ:ATYR ) Announces Top Line Results for the Phase III EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis September 15 2025 11:00 AM EDT Company Participants Ashlee Dunston - Director of Investor Relations & Corporate Communications Sanjay Shukla - President, CEO & Director Robert Bachman Jill Broadfoot - Chief Financial Officer Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research …
Read More
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR
Published: September 15, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $ATYR--aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR.
Read More
ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results
Published: September 15, 2025 by: Benzinga
Sentiment: Negative
Biotech firm aTyr Pharma Inc. ATYR plummeted over 81% at last check on Monday, with a session volume of 34.7 million compared to the average volume of 4.83 million as per data from Benzinga Pro.
Read More
BREAKING: aTyr Pharma Shares Plummet 80%; Investors Should Contact Block & Leviton to Potentially Recover Losses
Published: September 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating aTyr Pharma, Inc. (Nasdaq: ATYR) for potential securities law violations.
Read More
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofitimod in pulmonary sarcoidosis is higher than previously estimated with increased morbidity.
Read More
aTyr Pharma to Participate in April Investor Conferences
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2025. Details of the conferences appear below: Conference: Jones Healthcare and Technology Innovation Conference Date: April 8 – 9, 2025Location: Las Vegas, NVFormat: 1x1 Investor Meetings Conference: Piper Sandler Spring Biopharma Symposium Date: April 17, 2025Location: Boston, MAFormat: 1x1 Investor Meetings For more information on how to register, please …
Read More
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise.
Read More
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year?
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Atyr Pharma (ATYR) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
Read More
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D.
Read More
About aTyr Pharma, Inc. (ATYR)
- IPO Date
- Website https://www.atyrpharma.com
- Industry Biotechnology
- CEO Sanjay S. Shukla
- Employees 56